公司資料
CG Oncology, Inc. 股價、新聞與催化劑
- 股票代碼:
- CGON
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
77.11 USD (+2.77%)
收盤價
最後更新: 2026年8月17日
4.9B USD
市值
股價為何變動
As of Aug 17, 2026, CGON closed up 2.77% at $77.11. No new same-company headline was identified in the current news window.
公司概覽
Bladder-Cancer Immunotherapy
CG Oncology develops oncolytic immunotherapies for bladder cancer. Its lead candidate is administered directly into the bladder to selectively replicate in tumor cells and stimulate an antitumor immune response.
Cretostimogene Grenadenorepvec
Cretostimogene has been studied across more than 600 patients with non-muscle-invasive bladder cancer. Development spans BCG-unresponsive high-risk disease, BCG-exposed disease and intermediate-risk settings.
BCG-Unresponsive Registrational Program
CG Oncology is preparing a BLA based on cretostimogene monotherapy in high-risk, BCG-unresponsive disease, the candidate's initial planned regulatory indication.
Intermediate-Risk Disease
The Phase 3 PIVOT-006 study evaluates cretostimogene as an adjuvant monotherapy in intermediate-risk non-muscle-invasive bladder cancer.
Combination Development
The CORE-008 program evaluates cretostimogene with gemcitabine in BCG-exposed and BCG-unresponsive high-risk disease, broadening the candidate across treatment settings.
未來催化劑
- Topline Phase 3 PIVOT-006 data in intermediate-risk NMIBC in the first half of 2026.
- Initial Phase 2 CORE-008 Cohort CX data for cretostimogene plus gemcitabine at AUA 2026.
- Completion of the BLA submission for cretostimogene in high-risk BCG-unresponsive NMIBC in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。